Vergelijking

CagriSema vs. Eloralintide

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Metabool

CAS-nr.

geen gegevens

Molecuulmassa

geen gegevens

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

CagriSema

CagriSema combines two satiety pathways in one weekly injection: the amylin analogue cagrilintide and the GLP-1 agonist semaglutide. Both suppress appetite and food intake — together more than either component alone.

Eloralintide

Eloralintide selectively activates amylin receptors (preferentially AMY1R) and promotes satiety. The approach targets weight loss via the amylin axis, complementary to or independent of GLP-1 agents.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	CagriSema	Eloralintide
Duitsland	Niet goedgekeurd	Niet goedgekeurd
Verenigde Staten	Niet goedgekeurd	Niet goedgekeurd

Volledige vermeldingen

CagriSema

Volledige vermelding →

Eloralintide

Volledige vermelding →

Frequently asked questions

What is the difference between CagriSema and Eloralintide?: CagriSema is classified as "Metabool", while Eloralintide is classified as "Metabool". CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, CagriSema or Eloralintide?: The highest available evidence level is "Humane RCT" for CagriSema and "Humane RCT" for Eloralintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of CagriSema and Eloralintide in Germany and the United States?: Duitsland: CagriSema — Niet goedgekeurd, Eloralintide — Niet goedgekeurd. Verenigde Staten: CagriSema — Niet goedgekeurd, Eloralintide — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.

Country

CagriSema

Eloralintide

Duitsland

Niet goedgekeurd

Verenigde Staten

Niet goedgekeurd

Frequently asked questions

What is the difference between CagriSema and Eloralintide?

CagriSema is classified as "Metabool", while Eloralintide is classified as "Metabool". CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, CagriSema or Eloralintide?

The highest available evidence level is "Humane RCT" for CagriSema and "Humane RCT" for Eloralintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of CagriSema and Eloralintide in Germany and the United States?

Duitsland: CagriSema — Niet goedgekeurd, Eloralintide — Niet goedgekeurd. Verenigde Staten: CagriSema — Niet goedgekeurd, Eloralintide — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.